Your browser is no longer supported. Please, upgrade your browser.
KALA Kala Pharmaceuticals, Inc. daily Stock Chart
Kala Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-2.26 Insider Own1.10% Shs Outstand55.70M Perf Week-1.45%
Market Cap464.87M Forward P/E- EPS next Y-1.45 Insider Trans0.00% Shs Float33.90M Perf Month-17.29%
Income-90.40M PEG- EPS next Q-0.44 Inst Own89.30% Short Float19.26% Perf Quarter-22.57%
Sales4.50M P/S103.31 EPS this Y-10.60% Inst Trans-0.90% Short Ratio6.26 Perf Half Y-14.42%
Book/sh2.31 P/B3.52 EPS next Y18.10% ROA-44.10% Target Price- Perf Year133.62%
Cash/sh3.23 P/C2.52 EPS next 5Y- ROE-105.40% 52W Range3.24 - 14.68 Perf YTD120.33%
Dividend- P/FCF- EPS past 5Y-27.10% ROI-87.40% 52W High-44.62% Beta-
Dividend %- Quick Ratio11.30 Sales past 5Y67.90% Gross Margin44.30% 52W Low150.93% ATR0.59
Employees136 Current Ratio11.60 Sales Q/Q-61.90% Oper. Margin- RSI (14)47.08 Volatility5.89% 7.07%
OptionableYes Debt/Eq0.00 EPS Q/Q40.50% Profit Margin- Rel Volume1.09 Prev Close8.04
ShortableYes LT Debt/Eq0.56 EarningsAug 06 BMO Payout- Avg Volume1.04M Price8.13
Recom1.70 SMA200.18% SMA50-4.77% SMA200-9.40% Volume1,136,734 Change1.12%
Sep-14-20Downgrade Jefferies Buy → Hold $10
Jul-23-20Initiated Northland Capital Outperform
Jun-01-20Resumed Oppenheimer Outperform $21
May-27-20Reiterated H.C. Wainwright Buy $14 → $17
Mar-09-20Upgrade BofA/Merrill Neutral → Buy
Dec-17-19Downgrade BofA/Merrill Buy → Neutral $9 → $6
Mar-14-19Initiated Jefferies Buy $15
Oct-19-20 04:05PM  
Oct-15-20 11:06AM  
Oct-08-20 08:50AM  
Oct-06-20 08:48AM  
Oct-05-20 10:15AM  
Sep-30-20 10:01AM  
Sep-18-20 04:05PM  
Sep-10-20 08:00AM  
Sep-08-20 08:00AM  
Aug-27-20 11:00AM  
Aug-07-20 09:26AM  
Aug-06-20 09:15AM  
Aug-04-20 08:00AM  
Jul-30-20 04:01PM  
Jul-28-20 01:01PM  
Jul-17-20 04:01PM  
Jun-23-20 11:01AM  
Jun-10-20 08:00AM  
Jun-05-20 11:30AM  
Jun-02-20 08:41AM  
May-28-20 08:16AM  
May-27-20 08:00AM  
May-26-20 11:41AM  
May-19-20 11:30AM  
May-09-20 10:01PM  
May-07-20 10:05AM  
May-06-20 08:00AM  
May-05-20 12:00PM  
May-04-20 08:00AM  
May-01-20 11:30AM  
Apr-30-20 08:00AM  
Apr-17-20 04:01PM  
Apr-16-20 12:00PM  
Apr-08-20 11:01AM  
Apr-07-20 11:30AM  
Apr-03-20 04:01PM  
Mar-20-20 08:30PM  
Mar-15-20 04:24PM  
Mar-11-20 11:06AM  
Mar-10-20 11:02PM  
Mar-09-20 06:00AM  
Mar-06-20 10:11AM  
Feb-20-20 04:01PM  
Feb-12-20 11:30AM  
Feb-09-20 03:22PM  
Feb-06-20 11:53AM  
Feb-03-20 11:11AM  
Jan-30-20 11:10AM  
Jan-22-20 09:45AM  
Jan-15-20 08:00AM  
Jan-14-20 09:21AM  
Jan-08-20 08:00AM  
Dec-19-19 09:53PM  
Dec-12-19 04:11PM  
Nov-19-19 04:05PM  
Nov-07-19 08:25AM  
Nov-04-19 04:30PM  
Oct-21-19 04:05PM  
Oct-11-19 08:34AM  
Sep-25-19 08:40AM  
Sep-19-19 04:05PM  
Aug-29-19 08:00AM  
Aug-27-19 08:56AM  
Aug-23-19 11:24AM  
Aug-20-19 04:05PM  
Aug-19-19 07:08AM  
Aug-08-19 04:01PM  
Aug-06-19 03:40PM  
Jul-30-19 04:05PM  
Jul-22-19 08:02AM  
Jun-20-19 04:05PM  
Jun-13-19 03:11PM  
May-30-19 08:00AM  
May-17-19 04:05PM  
May-16-19 02:15PM  
May-09-19 08:15AM  
May-02-19 08:00AM  
Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. The company's lead product candidate is KPI-121 0.25% which has completed two Phase III clinical trials for the treatment of temporary relief of the signs and symptoms of dry eye disease; INVELTYS which has completed two Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was founded in 2009 and is headquartered in Watertown, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Trachtenberg EricSee RemarksJun 19Option Exercise5.1928,901149,99628,901Jun 22 04:06 PM
Reumuth MaryChief Financial OfficerJun 09Option Exercise2.6443,477114,77148,293Jun 11 04:58 PM
Brazzell Romulus KChief Medical OfficerApr 09Option Exercise2.9967,771202,377176,496Apr 13 08:38 AM
Chen HongmingChief Scientific OfficerMar 30Option Exercise2.3031,00071,30086,849Apr 01 04:43 PM
Bazemore ToddChief Operating OfficerMar 16Buy5.7510,00057,50010,000Mar 17 05:46 PM
Grunberg GregoryDirectorMar 13Buy7.892,534,85419,999,9982,534,854Mar 16 07:59 AM
Shah Rajeev M.DirectorMar 13Buy7.896,337,13549,999,99510,874,613Mar 13 06:47 PM
RA CAPITAL MANAGEMENT, L.P.DirectorMar 13Buy7.896,337,13549,999,99510,874,613Mar 13 06:45 PM